By What Percentage Did Pfizer’s Revenue & EBITDA Decline In The Last 5 Years?

+2.97%
Upside
27.78
Market
28.61
Trefis
PFE: Pfizer logo
PFE
Pfizer

 Pfizer’s Revenue & EBITDA Fell 29% & 19% Respectively In The Last 5 Years Due To Patent Losses & Divestiture

Pfizer_Q3

Pfizer_Q3_2

Relevant Articles
  1. Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
  2. Should You Pick Pfizer Stock At $30?
  3. Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
  4. Will Pfizer Stock See Higher Levels Post Q1 Earnings?
  5. Is Pfizer Stock Undervalued At $40?
  6. This Logistics Company Appears To Be A Better Pick Over Pfizer Stock

Have more questions about Pfizer? See the links below.

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Pfizer

 

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology